Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBUTEROL SULFATE vs SUSTAIRE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist resulting in bronchodilation via increased cyclic AMP synthesis and smooth muscle relaxation.
SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.
Treatment of bronchospasm in patients with reversible obstructive airway disease,Prophylaxis of exercise-induced bronchospasm,Acute asthma exacerbation (off-label)
FDA-approved for maintenance treatment of asthma in patients aged 6 years and older,FDA-approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults,Off-label: acute asthma exacerbations (as part of SMART therapy)
2 puffs (90 mcg/puff) via metered-dose inhaler q4-6h as needed; or 2.5 mg via nebulization q4-6h as needed
50 mg orally twice daily
Terminal elimination half-life is 3.8–6 hours after inhalation; in patients with hepatic impairment, half-life may be prolonged up to 8 hours.
Terminal elimination half-life of 8-12 hours in healthy adults; prolonged in renal impairment.
Extensively metabolized via catechol-O-methyltransferase (COMT) and conjugation; hepatic metabolism also occurs.
Budesonide: extensively metabolized in the liver via CYP3A4 to inactive metabolites; formoterol: partially metabolized via glucuronidation and O-demethylation, with minor CYP involvement.
Approximately 72% of an inhaled dose is recovered in urine as unchanged drug and metabolites (28% as sulfate conjugate) within 24 hours; fecal elimination accounts for less than 10%.
Primarily renal excretion (80-90% unchanged); minor biliary/fecal elimination (10-20%).
Approximately 10% bound to plasma proteins (primarily albumin).
Approximately 95% bound to albumin.
Mean Vd is 1.6–2.0 L/kg after IV administration, indicating extensive distribution into tissues.
0.2-0.3 L/kg; indicates limited extravascular distribution primarily in plasma and interstitial fluid.
Inhalation: 10–20% of the dose reaches the lungs systemically; oral: approximately 50% (first-pass metabolism; active metabolite formed).
Oral: 70-80% due to first-pass metabolism; intravenous: 100%.
No dose adjustment required for any degree of renal impairment
GFR 30-59 m L/min: 50 mg once daily; GFR 15-29 m L/min: 25 mg once daily; GFR <15 m L/min: not recommended
No dose adjustment required for any Child-Pugh class (A, B, or C)
Child-Pugh A: 50 mg twice daily; Child-Pugh B: 25 mg twice daily; Child-Pugh C: 12.5 mg once daily
Children 2-12 years: 1-2 puffs (90 mcg/puff) via MDI q4-6h as needed; or 0.15 mg/kg (min 1.25 mg, max 2.5 mg) via nebulization q4-6h as needed
Weight-based: 0.5 mg/kg orally twice daily, max 25 mg per dose
No specific dose adjustment; use lowest effective dose due to increased sensitivity to beta-adrenergic effects; monitor for tachycardia and tremor
Age >65 years: initiate at 25 mg twice daily; monitor renal function
No FDA black box warning.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. SUSTAIRE is contraindicated for use as primary therapy for acute asthma exacerbations. For asthma, use only as add-on therapy for patients not adequately controlled on low-to-medium dose inhaled corticosteroids (ICS) or whose disease severity warrants initiation of ICS and LABA.
Paradoxical bronchospasm may occur with excessive use,Cardiovascular effects (tachycardia, arrhythmia) especially with concurrent beta-blocker use,Hypokalemia risk with high doses,Use caution in patients with hyperthyroidism, diabetes, or seizure disorders
LABA-associated asthma-related death; cardiovascular effects (tachycardia, hypertension); paradoxical bronchospasm; hypokalemia; hyperglycemia; increased susceptibility to infections; adrenal insufficiency with systemic steroid withdrawal; acute asthma exacerbation management.
History of hypersensitivity to albuterol or any component
Primary treatment of status asthmaticus or acute asthma exacerbations; severe hypersensitivity to any ingredient.
No significant food interactions reported with albuterol sulfate. However, caffeine-containing foods or beverages (e.g., coffee, tea, cola) may theoretically potentiate stimulant effects such as increased heart rate or nervousness, though clinical significance is minimal. Patients should maintain normal dietary habits unless directed otherwise by their healthcare provider.
No significant food interactions. Grapefruit or grapefruit juice may increase systemic exposure; avoid excessive consumption. No specific dietary restrictions required.
Pregnancy category C. Inhaled albuterol is not associated with major congenital malformations in first trimester. Second and third trimester use may cause fetal tachycardia, hyperglycemia, and transient neonatal hypoglycemia. High-dose intravenous or oral use increases risk of uterine relaxation, maternal tachycardia, and potential placental hypoperfusion.
Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, hypotonia, and withdrawal syndrome with chronic use. Avoid use unless benefit outweighs risk.
Present in breast milk in low concentrations (M/P ratio unknown but likely <1). Limited data indicate no adverse effects in nursing infants. The American Academy of Pediatrics considers inhaled albuterol compatible with breastfeeding. Use lowest effective dose.
Excreted in breast milk; M/P ratio approximately 0.24. Limited data suggests low infant dose (0.5-1% maternal weight-adjusted dose). Monitor infant for drowsiness and feeding difficulties. Consider risk-benefit.
No routine dose adjustment required for inhaled albuterol. Pharmacokinetic changes in pregnancy (increased clearance, decreased free fraction) do not necessitate adjustment for standard inhaled doses. For continuous nebulization or high-dose use, monitor maternal heart rate and consider dose reduction if significant tachycardia occurs.
No standard dose adjustment recommended. Increased plasma volume may reduce drug levels; monitor clinical response. Avoid near term due to risk of neonatal depression. Use lowest effective dose for shortest duration.
Albuterol sulfate is a short-acting beta-2 agonist (SABA) used for acute bronchospasm relief. Onset of action is within 5-15 minutes by inhalation. Monitor for paradoxical bronchospasm, which may require discontinuation. Not indicated for maintenance therapy in asthma without concomitant inhaled corticosteroid. Can cause hypokalemia, especially at high doses; monitor potassium in at-risk patients. Use with caution in patients with cardiovascular disease, as beta-agonists can increase heart rate and blood pressure. Albuterol is pregnancy category C; use only if clearly needed. Nebulized albuterol is preferred for acute severe asthma exacerbations. Inhaled albuterol may be combined with ipratropium for acute exacerbations.
SUSTAIRE is an inhaled corticosteroid (ICS) used for maintenance treatment of asthma. It is not indicated for acute bronchospasm. Rinse mouth with water after each use to prevent oral candidiasis. Titrate to lowest effective dose to minimize systemic effects. Monitor for growth suppression in children and adrenal insufficiency during stress or prolonged use.
Use albuterol exactly as prescribed; it is for quick relief of wheezing and shortness of breath, not for daily prevention unless directed.,Rinse your mouth with water after using the inhaler to prevent dry mouth and throat irritation.,Shake the inhaler well before each use and prime it if not used for more than 2 weeks.,If you need more than 2 puffs twice a week for symptom relief, consult your doctor as your asthma may not be well-controlled.,Seek emergency medical help if you have worsening symptoms, chest tightness, or if the medication does not provide relief.,Avoid spraying albuterol into your eyes; if accidental contact occurs, rinse with water for several minutes.,Inform your doctor if you are pregnant, breastfeeding, or have heart problems, high blood pressure, seizures, or diabetes.,Store the inhaler at room temperature away from heat and open flame; do not puncture.
Use SUSTAIRE regularly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking SUSTAIRE without consulting your doctor, even if you feel better.,Keep track of your symptoms and peak flow if advised.,Seek medical help if your rescue inhaler is not working or you need more puffs than usual.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBUTEROL SULFATE vs SUSTAIRE, answered by our medical review team.
ALBUTEROL SULFATE is a Beta-2 Adrenergic Agonist (Bronchodilator) that works by Beta-2 adrenergic receptor agonist resulting in bronchodilation via increased cyclic AMP synthesis and smooth muscle relaxation.. SUSTAIRE is a Methylxanthine Bronchodilator that works by SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBUTEROL SULFATE and SUSTAIRE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBUTEROL SULFATE is: 2 puffs (90 mcg/puff) via metered-dose inhaler q4-6h as needed; or 2.5 mg via nebulization q4-6h as needed. The standard adult dose of SUSTAIRE is: 50 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBUTEROL SULFATE and SUSTAIRE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBUTEROL SULFATE is classified as Category C. Pregnancy category C. Inhaled albuterol is not associated with major congenital malformations in first trimester. Second and third trimester use may cause fetal tachycardia, hyperg. SUSTAIRE is classified as Category C. Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.